摘要
在近半个世纪的肝移植临床实践中,糖皮质激素(以下称激素)作为术后最常用的主流免疫抑制剂之一,在排斥反应的预防与治疗中占据极其重要的地位。然而,随着临床经验的积累,尤其是长期生存者的增多,人们发现肝移植术后长期应用激素具有一些严重的并发症,如高血压、骨质疏松、生长迟缓等。
出处
《中华外科杂志》
CAS
CSCD
北大核心
2008年第15期1123-1125,共3页
Chinese Journal of Surgery
参考文献22
-
1Margarit C, Martinez Ibanez V, Tormo R, et al. Maintenance immunosuppression without steroids in pediatric liver transplantation. Transplant Proc, 1989,21:2230-2231.
-
2Dunn SP, Falkenstein K, Lawrence JP, et al. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation,1994,57:544-547.
-
3Padbury RT, Gunson BK, Dousset B, et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation, 1993,55 : 789 -794.
-
4Stegall MD, Everson GT, Schroter G, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology, 1997,2 : 173-177.
-
5Gomez R, Moreno E, Colina F, et al. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients. J Hepatol, 1998,28 : 150-156.
-
6Mazzaferro V, Rondinara GF, Rossi G, et al. Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplant Proc, 1994,26:3557-3560.
-
7Lemmens HP, Langrehr JM, Blumhardt G, et al. Outcome following orthotopie liver transplantation in HBsAg-positive patients using shortor long-term immunoprophylaxis. Transplant Proe, 1994,26 : 3622 -3623.
-
8Vivarelli M, Burra P,Barba GL, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol, 2007,47 : 793-798.
-
9Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology, 1998,28:638-645.
-
10Belli LS, De Carlis L, Rondinara GF, et al. Prospective randomized trial of steroid withdrawal in liver transplant patients: preliminary report. Transpl Int, 1994,7 : S88-S90.
同被引文献25
-
1Llado L,Xiol X,Fiquerns J,et al.Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications:results from a prospective multicentor randomized study.J Hepatol,2006,44:710-716.
-
2Liu CL,Fan ST,Lo CM,et al.Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after livertransplantation:a protocol with early elimination of steroids and reduction of tacrolimus dosage,liver Transpl,2004,10:728-733.
-
3Toyoki Y,Hakamada K,Narumi S,et al.Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation:a single center experience.Transplant Proc,2004,36:2279-2281.
-
4Innoeenti F,Hepp J,Humeres R,et al.Rapid steroid taper and neoral monotherapy in liver transplantation in Chile:a step in the right direction? Transplant Proc,2004,36:1675-1676.
-
5Marubashi S,Dono K,Amano K,et al.Steroid-flee living-donor liver transplantation in adults.Transplantation,2005,80:704-706.
-
6Ringe B,Braun F,Schutz E,et al.A novel management strategy of steroid-free immunosuppression after liver transplantation:efficacy and safety of tacrolimus and mycophenolate mofetil.Transplantation,2001,71:508-515.
-
7Compston JE. Osteoporosis after liver transplantation. Liver Transpl,2003,9 : 321-330.
-
8Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation : 2003 international eonsensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation ,2003,75 : SS3-SS24.
-
9Greig P, Lilly L, Seudamore C, et al. Early steroid withdrawal after liver transplantation : the Canadian tacrolimus microemulsion cyclosporin A trial : 1 -year follow-up. Liver Transpl, 2003,9:587-595.
-
10Matinlauri II-I, Nurminen MM, Hockerstedt KA, et al. Changes in liver graft rejections over time. Transplant Proc, 2006,38 : 2663- 2669.
引证文献3
-
1鞠卫强,何晓顺,谈雅莉,巫林伟,邰强,胡安斌,王东平,马毅,朱晓峰,黄洁夫.两剂激素联合两剂达利珠单抗及他克莫司的免疫抑制方案在肝移植中的应用[J].中华外科杂志,2009,47(14):1064-1066. 被引量:4
-
2巫林伟,何晓顺,邰强,鞠卫强,王东平,朱晓峰,马毅,王国栋,胡安斌,黄洁夫.激素最小化免疫抑制方案在肝移植术后的应用[J].中华外科杂志,2010,48(7):492-495. 被引量:4
-
3巫林伟,何晓顺,郭志勇,邰强,鞠卫强,王东平,朱晓峰,马毅,王国栋,胡安斌.肝移植术后激素24小时撤离的安全性[J].中华普通外科学文献(电子版),2011,5(2):33-35. 被引量:2
二级引证文献9
-
1巫林伟,何晓顺,邰强,鞠卫强,王东平,朱晓峰,马毅,王国栋,胡安斌,黄洁夫.激素最小化免疫抑制方案在肝移植术后的应用[J].中华外科杂志,2010,48(7):492-495. 被引量:4
-
2鞠卫强,周健,何晓顺,王东平,巫林伟,郭志勇,朱晓峰,黄洁夫.供受者ABO血型不符的成人肝脏移植疗效评价[J].中华医学杂志,2011,91(36):2558-2560. 被引量:1
-
3鞠卫强,何晓顺,王东平,邓荣海,巫林伟,郭志勇,朱晓峰,黄洁夫.乙型肝炎表面抗原阳性供肝在肝移植中的应用[J].中华肝脏病杂志,2012,20(1):14-16. 被引量:8
-
4鞠卫强,何晓顺,郭志勇,朱晓峰,王东平,巫林伟,邰强,唐决,黄洁夫.肝胰十二指肠器官簇移植术后的免疫抑制治疗[J].中华普通外科学文献(电子版),2012,6(1):15-18. 被引量:1
-
5郭宁,吴忠均.免疫抑制药物在肝移植中的应用现状[J].中国组织工程研究,2012,16(18):3375-3379. 被引量:2
-
6徐莎莎,殷蓉,张峰,李相成.肝移植术后糖尿病的研究进展及影响因素[J].器官移植,2016,7(1):72-77. 被引量:10
-
7林良沫,黄春新,韩方璇.1例肝移植患者术后免疫抑制剂和抗HBV药物的药学监护[J].中国药物应用与监测,2016,13(6):345-348. 被引量:1
-
8周结学,刘东,吴家清,蒙善东,申升,李琴,郑克立.肾移植术后激素早期撤除患者的随访观察[J].新医学,2018,49(11):811-815. 被引量:3
-
9包玉娟,左祥荣.代谢综合征与肝移植的研究进展[J].实用器官移植电子杂志,2018,6(6):479-482. 被引量:1
-
1曹韵贞.感染HIV-1的长期生存者[J].国外医学(病毒学分册),1995,2(2):41-44. 被引量:1
-
2曹韵贞.长期感染HIV-1患者体内的病毒学和免疫学特征[J].传染病信息,1995,8(1):4-5.
-
3马曾辰.一个小儿肝肿瘤患者的长期随访记[J].健康促进,2004(5):34-35.
-
4薛峰,邱德凯.肝移植的内科指征及其临床进展[J].胃肠病学,2011,16(12):705-711. 被引量:1
-
5吕治林,孙仁华,严志焜.心脏、心肾联合移植术后长期生存者急性排斥反应2例报告[J].浙江实用医学,2004,9(2):138-138.
-
6胰岛素应用方案之一[J].糖尿病天地,2012(7):71-71.
-
7王峰.甘精胰岛素联用阿卡波糖治疗老年糖尿病患者的临床疗效及安全性分析[J].健康之路,2016,0(7):35-35.
-
8预防艾滋病母婴传播抗病毒药物应用方案[J].中国实用乡村医生杂志,2013(5):56-56.
-
9谢晶日,蔡林宏.抗病毒药物影响慢性乙型肝炎患者IFN-γ水平的研究进展[J].实用肝脏病杂志,2010,13(4):309-311. 被引量:3
-
10李福京.ACCOMPLISH之后门诊轻、中度抗高血压药的使用[J].临床医药实践,2009,18(2Z):1426-1427.